Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.

London, UK-based Vicebio raised $100 million in a Series B that will help to fund the development of its Molecular Clamp ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...